PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

Humanin: Research & Evidence

Early-Stage Research

Published research, clinical trial data, and evidence grading for Humanin across studied indications.

Back to Humanin overview

Research Summary

Humanin has approximately 8 human biomarker studies (all observational) and zero human therapeutic trials. Endogenous Humanin levels have been measured in circulation and tissue, showing correlations with aging and metabolic disease states. However, no study has administered synthetic Humanin to humans to test therapeutic efficacy. All therapeutic findings come from animal and cell-culture models. There is no registered clinical trial, no development program, and no path toward FDA approval as of March 2026.

Evidence by Indication (3 indications)

Indication Tier Trials Summary
Neuroprotection (Alzheimer's) Tier D 0 Animal and cell-culture data only; no human therapeutic trials
Metabolic syndrome Tier D 0 Human biomarker correlations only; no interventional studies
Anti-aging / cytoprotection Tier D 0 Endogenous levels measured as biomarker; no exogenous administration in humans

Graded using our evidence tier methodology.

Citations (5 sources)

  1. 1. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ Study

    Hashimoto Y, et al. (2001), Proceedings of the National Academy of Sciences

  2. 2. Humanin: a novel central regulator of peripheral insulin action Study

    Muzumdar RH, et al. (2009), PLoS ONE

  3. 3. Mitochondrial-derived peptides in aging and age-related diseases Review

    Kim SJ, et al. (2017), GeroScience

  4. 4. Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress Study

    Bachar AR, et al. (2010), Cardiovascular Research

  5. 5. Humanin peptide suppresses apoptosis by interfering with Bax activation Study

    Guo B, et al. (2003), Nature